LOXL2 and osteosarcoma: These findings highlight the significance of the FGF-23/miR-4463/LOXL2 axis in osteosarcoma progression and suggest that targeting this pathway may offer a novel therapeutic strategy to improve outcomes for patients with metastatic osteosarcoma.